SC
AXSM icon

SummitTX Capital’s Axsome Therapeutics AXSM Stock Holding History

SummitTX Capital’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.59M Buy
+15,304
New +$2.64M 0.08% 261
2025
Q4 		– Sell
-15,350
Closed -$1.86M – 703
2025
Q3 		$1.86M Buy
15,350
+12,641
+467% +$1.42M 0.08% 268
2025
Q2 		$283K Buy
+2,709
New +$287K 0.01% 628

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SummitTX Capital's AXSM Position: Q1 2026 in Review

SummitTX Capital opened a new position in Axsome Therapeutics (AXSM) in Q1 2026: 15,304 shares worth $2.59M. The stake represents 0.08% of the portfolio and ranks #261 among its holdings. This is a return to the name: SummitTX Capital previously reported a position in AXSM as recently as Q3 2025.

SummitTX Capital first reported a position in AXSM in Q2 2025 and has held it in 3 quarters since. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • SummitTX Capital held 15,304 shares of Axsome Therapeutics worth $2.59M as of Q1 2026.
  • Axsome Therapeutics was a new SummitTX Capital position in Q1 2026.
  • Axsome Therapeutics made up 0.08% of SummitTX Capital's portfolio in Q1 2026, its #261 holding.
  • SummitTX Capital first reported a position in Axsome Therapeutics in Q2 2025 and has held it in 3 quarters since.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on SummitTX Capital's 13F filing for Q1 2026, filed 15 May 2026.